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Analysis of registry data has provided key
insights into the changing demographics,
outcomes and treatments in cystic ﬁbrosis
(CF), but few studies have made use of
the great potential for cross-country com-
parisons. The linked study by Goss and
colleagues1 in Thorax does just this, using
registry data collected in the UK and the
USA to compare CF outcomes and use of
treatments on opposite sides of the
Atlantic. The study certainly makes for
uncomfortable reading from a UK per-
spective, but raises more questions than it
addresses. The analysis suggests that the
USA does better in terms of lung function
in children, and the authors conclude this
is due to more intensive treatment in the
early years. But is this interpretation
correct?
One of the most important ﬁndings of
the study is the striking gap in mean %
predicted FEV1 between the UK and the
USA at around 6 years, the age at which
lung function can be consistently collected
and measured reliably at all care centres.
The gap subsequently narrows and disap-
pears by age 30. Overall, children under
12 years of age in the UK had signiﬁcantly
lower lung function by 7.6 percentage
points compared with children in the
USA. This is a big difference in a study
where the large sample sizes mean that
the estimations of population level differ-
ences are quite precise, even for impre-
cisely measured outcomes such as %
predicted FEV1.
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In these initial attempts to compare
data collected in slightly different ways in
different countries, it is important to
ensure that the comparisons are valid. For
example, we must ensure that the ﬁndings
of this analysis are not biased by the possi-
bility that the samples used in the study
are not fully representative of the entire
CF populations in their respective
countries. Ascertainment bias is a
well-recognised problem in comparative
registry studies, and a key question with
regard to the study by Goss et al is the
extent to which the two populations can
be fairly compared. Comparative analysis
of coverage data in CF registries has
demonstrated how this can inﬂuence out-
comes when registries are differentially
representative of their respective total esti-
mated population.3
In the UK, the registry is estimated to
capture almost all of the CF population,
and any patients attending the National
Health Service clinics will have data rou-
tinely collected into the database.4 By
contrast, the US registry collects data on
patients seen in US accredited CF centres
and may have lower coverage.5 Older esti-
mates suggest that coverage in the US
registry was about 75% in the 1990s,3
during a period when the UK CF survey, a
precursor of the UK registry, had almost
complete coverage of the UK population.6
It is possible that the US registry does not
capture individuals across the full range of
the socio-economic spectrum to the same
extent as the UK registry due to the
nature of the healthcare system in the
USA, where the uninsured and those with
poorer access to care may be under-
represented. Thus, a consequence of the
high level of population coverage in the
UK, coupled with a universal healthcare
system, is that the UK registry may more
accurately represent more disadvantaged
groups, which we know from studies in
the UK and the USA have worse clinical
outcomes.4 7
Let us assume that the US dataset does
not represent the most disadvantaged to
the same extent: could this create the dif-
ferences observed? In order to explore
this further, we repeated the analysis in
the paper by Goss et al, removing 20% of
patients from the most disadvantaged
areas in the UK from the analysis. This
reduced the gap between the UK and the
USA, but not by much, suggesting that
ascertainment bias may potentially explain
some, but not most, of the difference in
childhood lung function. Concerns about
ascertainment aside, a key strength of the
study by Goss et al is the hard work that
has gone into harmonising the datasets to
ensure comparability, and the extent to
which the authors have tested the
robustness of their ﬁndings by stratifying
the analyses and undertaking appropriate
adjustment for important confounders in
their statistical models. For example, it is
plausible that differences in lung function
could arise due to variance in the ethnic
and genetic makeup of the US and UK
populations, but the authors address this
by restricting the analysis to white
patients, and also by repeating the analysis
using only patients who are homozygous
for F508del mutation. All the analyses
show similar results.
Understanding the narrowing of the
US–UK gap with increasing age is challen-
ging due to the cross-sectional nature of
the study, which is an important limita-
tion. We should not overinterpret the age
related trends in the ﬁgures since these do
not accurately represent longitudinal lung
function decline in the populations over
time. These cross-section differences con-
ﬂate cohort effects, and survivor bias,
whereby the cross-sectional comparisons
at older ages represent only the healthier
individuals who have survived to the
point of analysis. Without understanding
any survival differences, these patterns are
very hard to interpret. This brings us back
to the signiﬁcance of the early difference
in lung function, which represents the
‘cleanest’ comparison of the data, since
very few patients die in the ﬁrst few years
of life and so survivor bias does not com-
plicate the picture.
Overall, it seems most likely that the
UK–US gap in early lung function gap is
real, even if it may not be quite as great as
stated. So, how can we explain this differ-
ence? The authors suggest earlier and
more aggressive use of chronic pulmonary
therapies may be the reason, given the
large discrepancies in prescribing patterns
evident in the use of both nebulised saline
and DNase: children in the USA are much
more likely to receive these therapies.
However, there is no direct evidence pre-
sented to support this conclusion, and it is
a potentially dangerous leap of faith to
suggest that we should be systematically
delivering therapies to very young chil-
dren in the absence of good evidence of
effectiveness.
The authors’ conclusions will likely fuel
the debate around the effectiveness of
early intensive intervention in preschool
children with CF on the basis that this
may postpone or prevent early lung
disease8 but data informing the discussion
remain scant. A Cochrane review shows
short and intermediate term improve-
ments in lung function from DNase
therapy, as well as reductions in pulmon-
ary exacerbations, supporting its use in
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the general CF population, but a sub-
group analysis focusing on preschool chil-
dren was not possible given the dearth of
data in this age group.9 Inhaled hyper-
tonic saline, by contrast, has been shown
to improve quality of life and reduce pul-
monary exacerbations, but does not
appear to have a substantive effect on
lung function.10 A recent study of hyper-
tonic saline in children under 6 years of
age failed to show a difference in pulmon-
ary exacerbations, the primary study end-
point. Infant pulmonary function testing
performed as an exploratory outcome in a
subgroup did not demonstrate signiﬁcant
differences between groups except for a
small mean improvement in forced expira-
tory volume in 0.5 s in the active treat-
ment group.11
Plausible alternatives to explain the
lung function gap could relate to organisa-
tion of care, particularly frequency of
access to centre-based care. Children
attending large centres more frequently in
the early years in the UK do better,12 and
a challenge to services in the UK is to
achieve universally high standards of care
across the whole country. Data from the
US also suggest that the centres with
highest lung function scores for their
patients were characterised by more clinic
visits, more respiratory tract cultures and
frequent antibiotic treatment of patients,
particularly those considered to have mild
lung disease.13 14 Optimum treatment of
pulmonary exacerbations is a key factor in
terms of achieving better pulmonary out-
comes,15 and this may further explain
some of the differences seen in the study,
but these data are not comparable across
registries at the moment.
Clearly, more trials are needed in
younger children before clear conclusions
may be drawn regarding how superior
outcomes may be obtained in this age
group. While we can do more to unravel
the causal association between use of ther-
apies and long-term outcomes using regis-
try data, this requires longitudinal studies
and modern statistical approaches to
better establish causal pathways and elim-
inate the problem of confounding by indi-
cation in observational data.16
We welcome the study by Goss et al and
the questions that is raises. Harnessing the
rich data in CF registries offers the oppor-
tunity to improve the lives of patients with
CF, and cross-country comparisons have
changed policies and practice in CF in the
past.17 Just as centre-based comparisons
within countries have increased interest in
benchmarking and quality improvement
initiatives in an attempt to drive up stan-
dards,18–20 we hope that further cross-
national comparisons such as the one pre-
sented here can be used to highlight poten-
tially important differences in outcomes
and care for people with CF between
countries.
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